Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Feb 1;85(Suppl 2):15–18. doi: 10.1054/bjoc.2001.1984

A vision for the future?

M Baum 1
PMCID: PMC2375171  PMID: 11900211

Abstract

Systemic adjuvant therapy is recommended immediately following surgical removal of the primary tumour in the majority of patients with early breast cancer, to prevent the recurrence of distant metastases. Significant progress has been made in the development and evaluation of endocrine therapies for systemic adjuvant therapy. In pre- and perimenopausal women, ovarian ablation has proven to be a valuable treatment option, though not always desirable for young patients. Thus, reversible medical ovarian suppression with a luteinizing hormone releasing hormone agonist, such as goserelin (Zoladex™), may provide an attractive alternative for such patients. International trials have indicated that goserelin provides an important addition to the choice of adjuvant therapies now available to pre- and perimenopausal patients. For postmenopausal patients, it is hoped that the ATAC (Arimidex, tamoxifen, alone or in combination) trial will reveal whether or not the benefits of anastrozole (Arimidex™) observed in advanced disease, where it has proven to be well tolerated and at least as effective as tamoxifen in recent trials, will translate to the early setting to provide further management options for these patients. On the horizon is yet another exciting endocrine agent, ICI 182,780 (Fulvestrant™), which has also been shown to be as effective as anastrozole in advanced disease. In terms of the future, these agents are likely to provide additional valuable treatment choices for early breast cancer across the patient spectrum. © 2001 Cancer Research Campaign

Keywords: adjuvant therapy; early breast cancer; anastrozole; ICI 182,780; goserelin; premenopausal; postmenopausal

Full Text

The Full Text of this article is available as a PDF (40.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bines J., Oleske D. M., Cobleigh M. A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996 May;14(5):1718–1729. doi: 10.1200/JCO.1996.14.5.1718. [DOI] [PubMed] [Google Scholar]
  2. Boccardo F., Rubagotti A., Amoroso D., Mesiti M., Romeo D., Sismondi P., Giai M., Genta F., Pacini P., Distante V. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. boccardo@hp380.ist.unige.it. J Clin Oncol. 2000 Jul;18(14):2718–2727. doi: 10.1200/JCO.2000.18.14.2718. [DOI] [PubMed] [Google Scholar]
  3. Boccardo F., Rubagotti A., Perrotta A., Amoroso D., Balestrero M., De Matteis A., Zola P., Sismondi P., Francini G., Petrioli R. Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. Ann Oncol. 1994 Apr;5(4):337–342. doi: 10.1093/oxfordjournals.annonc.a058837. [DOI] [PubMed] [Google Scholar]
  4. Bonneterre J., Thürlimann B., Robertson J. F., Krzakowski M., Mauriac L., Koralewski P., Vergote I., Webster A., Steinberg M., von Euler M. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol. 2000 Nov 15;18(22):3748–3757. doi: 10.1200/JCO.2000.18.22.3748. [DOI] [PubMed] [Google Scholar]
  5. Fisher B., Costantino J. P., Wickerham D. L., Redmond C. K., Kavanah M., Cronin W. M., Vogel V., Robidoux A., Dimitrov N., Atkins J. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998 Sep 16;90(18):1371–1388. doi: 10.1093/jnci/90.18.1371. [DOI] [PubMed] [Google Scholar]
  6. Fisher B., Costantino J., Redmond C., Poisson R., Bowman D., Couture J., Dimitrov N. V., Wolmark N., Wickerham D. L., Fisher E. R. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989 Feb 23;320(8):479–484. doi: 10.1056/NEJM198902233200802. [DOI] [PubMed] [Google Scholar]
  7. Fisher B., Dignam J., Bryant J., DeCillis A., Wickerham D. L., Wolmark N., Costantino J., Redmond C., Fisher E. R., Bowman D. M. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996 Nov 6;88(21):1529–1542. doi: 10.1093/jnci/88.21.1529. [DOI] [PubMed] [Google Scholar]
  8. Fisher B., Powles T. J., Pritchard K. J. Tamoxifen for the prevention of breast cancer. Eur J Cancer. 2000 Jan;36(2):142–150. doi: 10.1016/s0959-8049(99)00269-5. [DOI] [PubMed] [Google Scholar]
  9. Goldhirsch A., Glick J. H., Gelber R. D., Senn H. J. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst. 1998 Nov 4;90(21):1601–1608. doi: 10.1093/jnci/90.21.1601. [DOI] [PubMed] [Google Scholar]
  10. Jonat W. Luteinizing hormone-releasing hormone analogues--the rationale for adjuvant use in premenopausal women with early breast cancer. Br J Cancer. 1998 Sep;78 (Suppl 4):5–8. doi: 10.1038/bjc.1998.754. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Katzenellenbogen B. S., Montano M. M., Ekena K., Herman M. E., McInerney E. M. William L. McGuire Memorial Lecture. Antiestrogens: mechanisms of action and resistance in breast cancer. Breast Cancer Res Treat. 1997 May;44(1):23–38. doi: 10.1023/a:1005835428423. [DOI] [PubMed] [Google Scholar]
  12. Masamura S., Adlercreutz H., Harvey H., Lipton A., Demers L. M., Santen R. J., Santner S. J. Aromatase inhibitor development for treatment of breast cancer. Breast Cancer Res Treat. 1995;33(1):19–26. doi: 10.1007/BF00666067. [DOI] [PubMed] [Google Scholar]
  13. Nabholtz J. M., Buzdar A., Pollak M., Harwin W., Burton G., Mangalik A., Steinberg M., Webster A., von Euler M. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol. 2000 Nov 15;18(22):3758–3767. doi: 10.1200/JCO.2000.18.22.3758. [DOI] [PubMed] [Google Scholar]
  14. Peto R., Boreham J., Clarke M., Davies C., Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet. 2000 May 20;355(9217):1822–1822. doi: 10.1016/S0140-6736(00)02277-7. [DOI] [PubMed] [Google Scholar]
  15. Powles T. J. Prognostic impact of amenorrhoea after adjuvant chemotherapy. Eur J Cancer. 1998 Apr;34(5):603–605. doi: 10.1016/s0959-8049(98)00039-2. [DOI] [PubMed] [Google Scholar]
  16. Pritchard K. I., Paterson A. H., Paul N. A., Zee B., Fine S., Pater J. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol. 1996 Oct;14(10):2731–2737. doi: 10.1200/JCO.1996.14.10.2731. [DOI] [PubMed] [Google Scholar]
  17. Rutqvist L. E. Controversial issues in adjuvant systemic therapy of early breast cancer. Acta Oncol. 1998;37(5):421–430. doi: 10.1080/028418698430368. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES